

Artificial Intelligence Transformed Analyses

# Clinical Solutions

### **About Us**

We deliver cutting-edge artificial intelligence solutions for healthcare and life sciences applications. Our innovative products and services drive efficiency, enhance diagnostic accuracy, and provide data-driven insights from digitally scanned images.

#### **Drug Discovery & Preclinical Research**

Our comprehensive AI-driven suite for drug discovery and development, streamlines pre-analytical quality control, facilitates tissue triage, and optimizes safety and efficacy assessments, accelerating breakthrough discoveries.

#### **Healthcare Solutions**

Our healthcare portfolio offers diagnostic, prognostic, and predictive tools that facilitate risk stratification and enable personalized therapy planning, thus improving treatment outcomes.

Write to solutions@airamatrix.com for more

## **AIRAQc**

#### Identification and Quantification of Artifacts in WSIs

Automate preanalytical quality checks to accept or flag images for reprocessing or rescanning based on set thresholds

High Performance


Achieve 95% sensitivity and 96% specificity, with a throughput of 10 WSIs per minute (1GB each) for fast and accurate analysis


Comprehensive Error Detection
Analyze WSIs to detect and quantify processing artifacts (Tissue Fold, Pen Marks/Dark Spots, Air Bubbles, Coverslip Line, Knife Line) and scanning

Customizable Thresholds
Set predefined thresholds based on the extent and type of errors to automatically mark images under accept, reprocess, or rescan

artifacts (Out of Focus, No Tissue, Missing Tissue)

- Detailed Analytics
  Generate detailed analytics about artifact quantification for insight into the overall WSI quality across your digitized pathology lab
- Seamless Integration
  Easily integrate with existing digital pathology workflows to streamline quality control without disrupting routine operations






## AIRAQc

## **Specifications**

Scanner Agnostic	Compatible with multiple image formats and scanners	
Analysis Mode	Auto, Manual	
Operation Mode	Rapid, Comprehensive	
Stains	H&E, IHC	
Deployment	Cloud, On-Premise	
Species	All	
Export Results	CSV, Excel	







## **AIRAProstate**

#### **Platform for Prostate Image Analysis**

Automate Gleason grading, ISUP grouping, and prognostic marker quantification in CNB and RP for accurate risk stratification and better treatment decisions

- AI-Powered Insights
  - Leverage deep learning models trained on 10,000+ patient datasets for high-accuracy analysis, achieving upto 0.92 Quadratic Weighted Kappa
- MRN-Based Slide Review
  Review all slides for an MRN in one place for a comprehensive case assessment, enabling quicker, more informed decision-making
- Comprehensive Case History View
  Get a holistic view of a patient's case by accessing the history of all associated MRNs for an in-depth diagnostic overview when making critical treatment decisions
- Advanced Viewer Capabilities
  Utilize features including hands-free navigation, annotation tools, and synced image comparison for ease of viewing and analysis
- Report Generation
  Generate reports with customizable formats for manual or automated image analysis






## **AIRAProstate**

## **Specifications**

Scanner Agnostic	Compatible with multiple image formats and scanners  Auto, Manual	
Analysis Mode		
Specimen	Core Needle Biopsy, Radical Prostatectomy	
Stain	H&E	
Findings	ISUP Grade Group, Primary and Secondary Gleason Patterns, Cribriform, Peri-Neural Invasion, and Neuro-endocrine PCa	
Deployment	Cloud, On-Premise	
Export Results	CSV, PDF	







## **AIRAPredict**

### **Explainable Solutions to Predict Molecular Marker Expression**

Predict molecular subtypes directly from routine H&E-stained tissue images, optimizing tissue requirements, costs, and turnaround time

- High Confidence Predictions
  Delivers up to 91% AUC for accurate and reliable risk assessment
- Predict Molecular Alterations
  Accurately predict PTEN Deletion, ERG Fusion, and BRCA-2 Expression from H&E-stained prostate biopsy and radical prostatectomy images
- Ground Truth Data
  Trained on ground truth from IHC and transcriptomic assay outcomes, ensuring reliability
- Patient Screening
  Screen patients for relevant genomic alterations without expensive genomic sequencing
- Cost and Time Optimization
  Efficient triaging helps reduce costs and significantly improve turnaround time







## **AIRAPredict**

## **Specifications**

Scanner Agnostic	Compatible with multiple image formats and scanners
Analysis Mode	Auto, Manual
Specimen	Core Needle Biopsy, Radical Prostatectomy
Stains	H&E
Findings	PTEN Deletion, ERG Fusion, BRCA-2 Expression
Deployment	Cloud, On-Premise
Export Results	CSV, PDF





#### **AIRAStrat**

#### Risk Stratification in Prostate Cancer

Multimodality-trained AI solutions for risk stratification at biopsy and post-RP. Endpoint prediction of tumor upgrades, BCR, metastasis, and metastasis-free survival

- Advanced Risk Stratification
  Trained on multimodal data with clinical outcomes as ground truth, achieving up to 0.91 AUC and outperforming conventional methods, including genomic classifiers
- Smarter Patient Classification
  Enhances active surveillance decisions, reducing unnecessary treatments
- Optimized Post-Surgical Care
  Guides therapy selection to minimize treatment-related complications
- Metastatic Risk Heatmap
  Overlay on images highlights metastatic
  risk levels, integrating clinical data with
  histopathology for better risk stratification
  and informed decision-making
- Metastasis Prediction
  Offers metastasis-free survival insights by integrating clinical and pathological data for personalized prognosis and long-term cancer management



## **AIRAStrat**

### **Specifications**

	opecinications			
	Scanner Agnostic	Compatible with multiple image formats and scanners		
	Analysis Mode	Auto, Manual		
	Specimen	Core Needle Biopsy, Radical Prostatectomy		
	Stains	Н&Е		
	Deployment	Cloud, On-Premise	BIOMARKER Blomarker BRCA2 Biallelic Loss Positive	
	Export Results	CSV, PDF	ERG Rearrangement Negative PTEN Delection Positive  Note: Positive Score × 0.5  ADVERSE PATHOLOGY	
	Evaluation Metric	AUC, F1 Score		



#### CLINICAL INTERPRETATION —

Prognostic Risk
The patient has a 25.2% risk of developing distant metastasis within 5 years of radical prostatectomy.

Patients with BRCA2 mutations who are diagnosed with prostate cancer, particularly with a high Cleason grade (Grade Group 4 or 5, Gleason Score 28), face a significantly elevated risk compared to those without BRCA2 mutations.

Key risk factors and considerations include:

Aggressiveness of Cancer.
BRCA2-associated prostate cancers are more likely to be aggressive, with faster progression and a higher likelihood of metastasis.

Risk of Metastasis:
Studies suggest that men with BRCA2 mutations have a 3-4 times higher risk of developing metastatic prostate cancer than non-carriers, particularly in high-grade cases.


Copyright © AIRA Matrix Private Limited


## Custom AI Development

#### Custom AI Models Built for Your Needs

Get tailored, efficient solutions with our custom AI development services for short-term histopathology studies

- Accelerated Delivery
  40% faster turnaround with lower development costs using ready-to-use AI models
- 100+ Pre-Built Models
  Leverage a vast library of pre-trained models for rapid customization
- Smart Data Creation
  Generate training data rapidly with foundation model-based tools
- Stain Adaptation
  Easily fine-tune the model for new stain variations
- Active learning to accelerate model training





solutions@airamatrix.com



Artificial Intelligence
Transformed Analyses